FindTrial
Sign In

ADG106

DRUG5 trials

Sponsors

Adagene Inc, Adagene (Suzhou) Limited, National University Hospital, Singapore

Conditions

Advanced Solid TumorAdvanced/Metastatic Solid TumorsHER2-negative Breast CancerMetastatic Non Small Cell Lung CancerNon-Hodgkin LymphomaSolid TumorSolid Tumors, Non-Hodgkin Lymphoma

Phase 1

Study of CD137 Agonist ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
CompletedNCT03707093
Adagene IncSolid Tumors, Non-Hodgkin Lymphoma
Start: 2018-09-17End: 2022-09-30Updated: 2022-10-18
Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
CompletedNCT03802955
Adagene (Suzhou) LimitedNon-Hodgkin Lymphoma, Solid Tumor
Start: 2018-12-20End: 2021-11-01Updated: 2023-04-24
A Phase 1b/2 Study of ADG116, ADG116 Combined With Anti-PD-1 Antibody or Anti-CD137 Antibody in Solid Tumors Patients
CompletedNCT04501276
Adagene IncAdvanced/Metastatic Solid Tumors
Start: 2020-09-23End: 2025-11-30Updated: 2026-01-08
A Study to Evaluate the Combination of Nivolumab With ADG106 in Metastatic NSCLC
NCT05236608
National University Hospital, SingaporeMetastatic Non Small Cell Lung Cancer
Start: 2021-11-12End: 2024-05-31Target: 53Updated: 2022-03-25
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer
Active, not recruitingNCT05275777
National University Hospital, SingaporeAdvanced Solid Tumor, HER2-negative Breast Cancer
Start: 2022-05-19End: 2030-02-28Target: 66Updated: 2025-07-25

Related Papers

A phase Ib/II study of an anti-CD137 agonist antibody ADG106 in combination with weekly paclitaxel and dose-dense doxorubicin/cyclophosphamide.
Journal of Clinical Oncology2024-06-01
Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin's lymphoma.
2024-02-079 citations
753 A phase 1b/2 study of a novel anti-CTLA-4 NEObody<sup>TM</sup> ADG116 monotherapy and in combination with toripalimab (Tori; Anti-PD-1 Antibody) in patients with advanced/metastatic solid tumors
Regular and Young Investigator Award Abstracts2022-11-01
773 A phase 1b/2, open-label, dose escalation and expansion study of an anti-CTLA-4 NEOBody<sup>TM</sup> ADG116 in combination with pembrolizumab (anti-PD-1 antibody) in patients with advanced/metastatic solid tumors: a preliminary update
Regular and Young Investigator Award Abstracts2022-11-01
Phase 1 study of ADG126, a novel masked anti-CTLA-4 SAFEbody, that combines tumor-localized activation with strong T<sub>reg</sub> depletion and soft ligand blocking in patients with advanced solid tumors.
Journal of Clinical Oncology2022-06-01
Identification of a predictive biomarker and two pharmacodynamic biomarkers to ADG106 treatment, a novel anti-CD137 agonist antibody, in phase I clinical trials.
Journal of Clinical Oncology2021-05-202 citations
A phase I, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced solid tumors or relapsed/refractory non-Hodgkin lymphoma.
Journal of Clinical Oncology2020-05-207 citations
Abstract A082: A phase 1, first-in-human, dose-escalation study of ADG106, a fully human anti-CD137 agonistic antibody, in subjects with advanced or metastatic solid tumors and/or relapsed/refractory non-Hodgkin lymphoma
Molecular Cancer Therapeutics2019-12-011 citations